Recent actions by the FDA and NIH in response to the current political climate have left key stakeholders in clinical trials ...

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

With an increased need for operational efficiency, while also leveraging new technologies such as AI, the landscape of ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

The long-held practice is effective in pinpointing the emergence of known and unknown risks to clinical development, study ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Florence has been issuing its State of Technology Enabled Clinical Trials Report for five years now, so there is contextual ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native ...

Phase III EV-302/KEYNOTE-A39 trial confirms that the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) provides sustained and significant overall survival and progression-free ...